IGMS News and Press, IGM Biosciences Inc. From 12/08/23

2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...

2023-12-06 12:40:32 ET More on Medivir AB Historical earnings data for Medivir AB Financial information for Medivir AB For further details see: Medivir says IGM Biosciences cutbacks won't impact lead product fostrox

2023-12-05 16:42:48 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences GAAP EPS of -$1.04 beats by $0.21, revenue of $0.51M misses by $0.34M IGM Biosciences Chief Commercial Officer discloses sale of 93...

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indi...

Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM , Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm , whereby the resolutio...

Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical ne...

2023-11-14 01:48:58 ET More on IGM Biosciences IGM Biosciences: What Causes The Very High Short Interest In This Ticker IGM Biosciences Chief Commercial Officer discloses sale of 935 company shares IGM Bioscience announces departure of chairman Michael Loberg ...

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnol...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...